Abstract:Objective: The traditional Chinese medicine Anluohuaxianwan (ALHXW) has been used to treat liver fibrosis induced by chronic hepatitis B virus (HBV) infection. However, the anti-fibrosis mechanisms of ALHXW remain to be investigated. This study used a rat model of carbon tetrachloride (CCl(4))-induced liver fibrosis to explore the potential antifibrogenic mechanisms of ALHXW. Methods: Twenty-seven male Wistar rats were randomly assigned to control group, model group, and treatment group (n = 9 per group). Rats in the model and treatment group were injected intraperitoneally with 40% CCl(4)(2 ml/kg), and rats in the control group were administered saline twice a week for 6 weeks. Starting at week 4 following model construction, rats in the treatment group received daily gavages with ALHXW solution (concentration 0.15 g/ml) daily, while rats in the control and model groups were given saline for a total of 6 weeks. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were measured from blood samples collected at the end of weeks 3, 6 and 9. Histopathological examination of liver tissue was performed to evaluate liver fibrosis at week 9. At the same time, the mRNA expression of TGF-β1 and Smads in liver tissues was quantified by real-time reverse transcription polymerase chain reaction (RT-PCR), and TGF-β1 protein level in the liver was measured by Western blot. Inter-group comparison was performed using analysis of variance (ANOVA) when the continuous data were normally distributed and satisfied the homogeneity of variance; otherwise, nonparametric tests were used. Categorical data were compared between groups using nonparametric tests. Results: ALHXW markedly alleviated liver injury in the treatment group after 3 weeks of therapy as indicated by a significantly reduced level of ALT compared with the model group [(162.98 ± 73.14)U/L vs (322.52 ± 131.76)U/L, P = 0.047], and a 39.8% reduction in AST level compared with the model group[ (537.56 ± 306.06)U/L vs (892.98 ± 358.19)U/L, P = 0.053]. Moreover, at the end of the 6-week therapy, histopathological diagnosis showed that liver fibrosis was significantly reduced in the ALHXW-treated group compared with that in the model group (P = 0.002). The relative expression of TGF-β1 mRNA and protein in the liver were significantly lower in ALHXW-treated rats than that in model rats (1.34 ± 0.31 vs 1.78 ± 0.45, P = 0.025; 0.39 ± 0.02 vs 0.57 ± 0.04, P = 0.003). Conclusion: ALHXW treatment can reverse CCl(4)-induced liver fibrosis in rats. Its mechanisms of anti-fibrosis may occur through the inhibition of TGF-β1 synthesis and TGF-β1/Smads signaling pathway, which in turn suppress the activation of hepatic stellate cells and thereby reverses fibrosis.

Effect of oxymatrine combined with compound salvia miltiorrhiza on serological markers of liver fibrosis, tumor necrosis factor-alpha and leptin levels in patients with chronic hepatitis B

A Clinical Research on Oxymatrine for the Treatment of Chronic Hepatitis B

Efficacy of different therapeutic modalities for patients with acute-on-chronic liver failure induced by hepatitis B

Effects of oxymatrine on the serum levels of T helper cell 1 and 2 cytokines and the expression of the S gene in hepatitis B virus S gene transgenic mice: a study on the anti-hepatitis B virus mechanism of oxymatrine

[A Clinical Trial of Oxymatrine in Treating Chronic Viral Hepatitis Type B].

[Oxymatrine in the Treatment of Chronic Hepatitis B for One Year: a Multicenter Random Double-Blind Placebo-Controlled Trial].

[Effects of Oxymatrine on Serum Levels of Th1/Th2 Type Cytokines in HBsAg Transgenic Mice].

Oxymatrine Therapy for Chronic Hepatitis B: a Randomized Double-Blind and Placebo-Controlled Multi-Center Trial.

Capsule Oxymatrine in Treatment of Hepatic Fibrosis Due to Chronic Viral Hepatitis: A Randomized, Double Blind, Placebo-Controlled, Multicenter Clinical Study

Effect of Xuezhikang Combined with Silibinin on Serum Lipids of Fatty Liver Patients

Clinical Observation on 46 Cases of Type 2 Diabetes Mellitus Complicated with Fatty Liver Treated by Yiqi Yangyin and Huoxue Herbal Medicines

Effects of Oxymatrine on Experimental Hepatic Fibrosis and Its Mechanism in Vivo

Short-Term Effect Of Combined Therapy With Jinlong Capsule ((Sic)) And Transcatheter Arterial Chemoembolization On Patients With Primary Hepatic Carcinoma And Its Influence On Serum Osteopontin Expression

Effect of Oxymatrine on Collagen Synthesis and Expression of TGF-β1 in an Immune Hepatic Fibrosis Model

A proteomics-based study of the mechanism of oxymatrine to ameliorate hepatic fibrosis in mice

The effect of oxymatrine on serum cholinesterase of patients with chronic viral hepatitis or cirrhosis post of hepatitis

Antifibrotic effects of a herbal combination regimen on hepatic fibrotic rats

Sophora flavescens-Astragalus mongholicus herb pair in the progression of hepatitis, cirrhosis, and hepatocellular carcinoma: a possible mechanisms and relevant therapeutic substances

[Effects of Anluohuaxianwan on Transforming Growth Factor-Β1 and Related Signaling Pathways in Rats with Carbon Tetrachloride-Induced Liver Fibrosis].

Effect of Anluohuaxian Tablet Combined with Γ-Ifn on Schistosomal Liver Fibrosis

Clinical efficacy and safety of TCM prescriptions combined with nucleoside (acid) analogues in treating chronic hepatitis B: a meta-analysis